@article{TLCR33703,
author = {Yuan Zhao and Bing Wan and Tianli Zhang and Yangyang Xu and Hongbing Liu and Tangfeng Lv and Fang Zhang and Ping Zhan and Yong Song},
title = {Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {6},
year = {2019},
keywords = {},
abstract = {Background: The main aim of this study was to evaluate the efficiency of second-line chemotherapy irinotecan (CPT-11), topotecan (TPT), paclitaxel (PTX) and docetaxel (DTX) in small cell lung cancer (SCLC) patients who have failure to the first-line standard treatment. The secondary aim was to evaluate the independent prognostic factors of patients who received a second line treatment.
Methods: Retrospective analysis of 116 patients who received second-line chemotherapy. Patients were divided into 4 groups according to the therapy they were treated with, which were CPT-11, TPT, PTX and DTX. Progress free survival (PFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) were evaluated for each group. Patients’ data of clinical character and blood index were collected, and the prognostic factors were assessed both at univariate and multivariate levels.
Results: Patients treated with CPT-11 achieved the best median PFS and OS of 91 and 595 days, while the median PFS of TPT, PTX and DTX were 74.5, 81 and 50 days respectively. The median OS of them were 154, 168.5 and 184 days respectively. The survival curves of OS were significantly different (P=0.0069). The reaction to second-line therapy is positively correlate to the reaction to first-line therapy (P=0.012). In the multivariate analysis, treatment free interval (TFI) },
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/33703}
}